Морфофункциональный анализ роли эпикардиальной жировой ткани в формировании парадокса ожирения при хронической сердечной недостаточности

В статье на основе доступной современной медицинской литературы обобщены данные научных исследований морфофункционального значения эпикардиальной жировой ткани (ЭЖТ) в здоровом организме и при развитии сердечной недостаточности, выполнен анализ вероятности и достоверности формирования парадокса ожирения, а также обсуждены возможные морфофункциональные механизмы его развития. Рассмотрены и проанализированы последовательности возникновения и развития парадокса ожирения с позиции оценки формирования защитных функций нормального фенотипа ЭЖТ, предложены пути дальнейшей исследовательской работы в этом направлении для глубокого анатомо-физиологического анализа и установления морфофункциональной роли ЭЖТ в приспособительных механизмах трофического обеспечения миокарда, что может являться важной частью выявления звеньев патогенетической связи ожирения и ХСН и, следовательно, может способствовать улучшению результатов лечения пациентов данной категории.

1. Шальнова С.А., Драпкина О.М. Значение исследования ЭССЕ-РФ для развития профилактики в России. Кардиоваскулярная терапия и профилактика. 2020;19(3):209-15. DOI: 10.15829/1728-8800-2020-2602

2. Савина А.А., Фейгинова С.И. Распространенность ожирения среди населения Российской Федерации: период до пандемии COVID-19. Социальные аспекты здоровья населения. 2022;68(5):4. DOI: 10.21045/2071-5021-2022-68-5-4

3. Powell-Wiley TM, Poirier P, Burke LE, Després J-P, Gordon-Larsen P, Lavie CJ et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984–1010. DOI: 10.1161/CIR.0000000000000973

4. Поляков Д.C., Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Артемьева Е.Г. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА -ХСН. Кардиология. 2021;61(4):4-14. DOI: 10.18087/cardio.2021.4.n1628

5. Zhai AB, Haddad H. The impact of obesity on heart failure. Current Opinion in Cardiology. 2017;32(2):196–202. DOI: 10.1097/HCO.0000000000000370

6. Lawson CA, Zaccardi F, Squire I, Okhai H, Davies M, Huang W et al. Risk Factors for Heart Failure: 20-Year Population-Based Trends by Sex, Socioeconomic Status, and Ethnicity. Circulation: Heart Failure. 2020;13(2):e006472. DOI: 10.1161/CIRCHEARTFAILURE.119.006472

7. Sharma A, Lavie CJ, Borer JS, Vallakati A, Goel S, Lopez-Jimenez F et al. Meta-Analysis of the Relation of Body Mass Index to All-Cause and Cardiovascular Mortality and Hospitalization in Patients With Chronic Heart Failure. The American Journal of Cardiology. 2015;115(10):1428–34. DOI: 10.1016/j.amjcard.2015.02.024

8. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. Journal of the American College of Cardiology. 2001;38(3):789–95. DOI: 10.1016/S0735-1097(01)01448-6

9. Fonarow GC, Srikanthan P, Costanzo MR, Cintron GB, Lopatin M. An obesity paradox in acute heart failure: Analysis of body mass index and inhospital mortality for 108927 patients in the Acute Decompensated Heart Failure National Registry. American Heart Journal. 2007;153(1):74–81. DOI: 10.1016/j.ahj.2006.09.007

10. Horwich TB, Fonarow GC, Clark AL. Obesity and the Obesity Paradox in Heart Failure. Progress in Cardiovascular Diseases. 2018;61(2):151–6. DOI: 10.1016/j.pcad.2018.05.005

11. Doesch C, Suselbeck T, Leweling H, Fluechter S, Haghi D, Schoenberg SO et al. Bioimpedance Analysis Parameters and Epicardial Adipose Tissue Assessed by Cardiac Magnetic Resonance Imaging in Patients With Heart Failure. Obesity. 2010;18(12):2326–32. DOI: 10.1038/oby.2010.65

12. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nature Reviews Cardiology. 2022;19(9):593–606. DOI: 10.1038/s41569-022-00679-9

13. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nature Clinical Practice Cardiovascular Medicine. 2005;2(10):536–43. DOI: 10.1038/ncpcardio0319

14. Marchington JM, Mattacks CA, Pond CM. Adipose tissue in the mammalian heart and pericardium: Structure, foetal development and biochemical properties. Comparative Biochemistry and Physiology Part B. 1989;94(2):225–32. DOI: 10.1016/0305-0491(89)90337-4

15. Perez-Miguelsanz J, Jiménez-Ortega V, Cano-Barquilla P, Garaulet M, Esquifino AI, Varela-Moreiras G et al. Early Appearance of Epicardial Adipose Tissue through Human Development. Nutrients. 2021;13(9):2906. DOI: 10.3390/nu13092906

16. Sacks HS, Fain JN, Bahouth SW, Ojha S, Frontini A, Budge H et al. Adult Epicardial Fat Exhibits Beige Features. The Journal of Clinical Endocrinology & Metabolism. 2013;98(9):E1448–55. DOI: 10.1210/jc.2013-1265

17. Chen P-S, Turker I. Epicardial Adipose Tissue and Neural Mechanisms of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology. 2012;5(4):618–20. DOI: 10.1161/CIRCEP.112.974956

18. Saely CH, Geiger K, Drexel H. Brown versus White Adipose Tissue: A Mini-Review. Gerontology. 2012;58(1):15–23. DOI: 10.1159/000321319

19. Patel KHK, Hwang T, Se Liebers C, Ng FS. Epicardial adipose tissue as a mediator of cardiac arrhythmias. American Journal of Physiology-Heart and Circulatory Physiology. 2022;322(2):H129–44. DOI: 10.1152/ajpheart.00565.2021

20. Martínez-Sánchez N. There and Back Again: Leptin Actions in White Adipose Tissue. International Journal of Molecular Sciences. 2020;21(17):6039. DOI: 10.3390/ijms21176039

21. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Archives of Medical Science. 2013;9(2):191–200. DOI: 10.5114/aoms.2013.33181

22. Golozoubova V, Cannon B, Nedergaard J. UCP1 is essential for adaptive adrenergic nonshivering thermogenesis. American Journal of Physiology-Endocrinology and Metabolism. 2006;291(2):E350–7. DOI: 10.1152/ajpendo.00387.2005

23. Wu J, Boström P, Sparks LM, Ye L, Choi JH, Giang A-H et al. Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in Mouse and Human. Cell. 2012;150(2):366–76. DOI: 10.1016/j.cell.2012.05.016

24. Ojha S, Fainberg HP, Wilson V, Pelella G, Castellanos M, May ST et al. Gene pathway development in human epicardial adipose tissue during early life. JCI Insight. 2016;1(13):e87460. DOI: 10.1172/jci.insight.87460

25. Thoonen R, Ernande L, Cheng J, Nagasaka Y, Yao V, Miranda-Bezerra A et al. Functional brown adipose tissue limits cardiomyocyte injury and adverse remodeling in catecholamine-induced cardiomyopathy. Journal of Molecular and Cellular Cardiology. 2015;84:202–11. DOI: 10.1016/j.yjmcc.2015.05.002

26. Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nature Reviews Endocrinology. 2015;11(6):363–71. DOI: 10.1038/nrendo.2015.58

27. Nerlekar N, Muthalaly RG, Wong N, Thakur U, Wong DTL, Brown AJ et al. Association of Volumetric Epicardial Adipose Tissue Quantification and Cardiac Structure and Function. Journal of the Ameri can Heart Association. 2018;7(23):e009975. DOI: 10.1161/JAHA.118.009975

28. Sörensen J, Harms HJ, Aalen JM, Baron T, Smiseth OA, Flachskampf FA. Myocardial Efficiency. JACC: Cardiovascular Imaging. 2020;13(7):1564–76. DOI: 10.1016/j.jcmg.2019.08.030

29. Birkenfeld AL, Jordan J, Dworak M, Merkel T, Burnstock G. Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts. Pharmacology & Therapeutics. 2019;194:132–44. DOI: 10.1016/j.pharmthera.2018.08.015

30. Pezeshkian M, Noori M, Najjarpour-Jabbari H, Abolfathi A, Darabi M, Darabi M et al. Fatty Acid Composition of Epicardial and Subcutaneous Human Adipose Tissue. Metabolic Syndrome and Related Disorders. 2009;7(2):125–32. DOI: 10.1089/met.2008.0056

31. Marchington JM, Pond CM. Site-specific properties of pericardial and epicardial adipose tissue: the effects of insulin and high-fat feeding on lipogenesis and the incorporation of fatty acids in vitro. International Journal of Obesity. 1990;14(12):1013–22. PMID: 2086494

32. Ernault AC, Meijborg VMF, Coronel R. Modulation of Cardiac Arrhythmogenesis by Epicardial Adipose Tissue. Journal of the American College of Cardiology. 2021;78(17):1730–45. DOI: 10.1016/j.jacc.2021.08.037

33. Patel VB, Shah S, Verma S, Oudit GY. Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. Heart Failure Reviews. 2017;22(6):889–902. DOI: 10.1007/s10741-017-9644-1

34. Antonopoulos AS, Antoniades C. The role of epicardial adipose tissue in cardiac biology: classic concepts and emerging roles. The Journal of Physiology. 2017;595(12):3907–17. DOI: 10.1113/JP273049

35. Salazar J, Luzardo E, Mejías JC, Rojas J, Ferreira A, Rivas-Ríos JR et al. Epicardial Fat: Physiological, Pathological, and Therapeutic Implications. Cardiology Research and Practice. 2016;2016:1291537. DOI: 10.1155/2016/1291537

36. Antonopoulos AS, Margaritis M, Verheule S, Recalde A, Sanna F, Herdman L et al. Mutual Regulation of Epicardial Adipose Tissue and Myocardial Redox State by PPAR-γ/Adiponectin Signalling. Circulation Research. 2016;118(5):842–55. DOI: 10.1161/CIRCRESAHA.115.307856

37. Antonopoulos AS, Margaritis M, Coutinho P, Shirodaria C, Psarros C, Herdman L et al. Adiponectin as a Link Between Type 2 Diabetes and Vascular NADPH Oxidase Activity in the Human Arterial Wall: The Regulatory Role of Perivascular Adipose Tissue. Diabetes. 2015;64(6):2207–19. DOI: 10.2337/db14-1011

38. D’Marco L, Puchades MJ, Gorriz JL, Romero-Parra M, Lima-Martínez M, Soto C et al. Epicardial Adipose Tissue, Adiponectin and Leptin: A Potential Source of Cardiovascular Risk in Chronic Kidney Disease. International Journal of Molecular Sciences. 2020;21(3):978. DOI: 10.3390/ijms21030978

39. Song Y, Song F, Wu C, Hong Y-X, Li G. The roles of epicardial adipose tissue in heart failure. Heart Failure Reviews. 2022;27(1):369–77. DOI: 10.1007/s10741-020-09997-x

40. Peacock WF. Novel biomarkers in acute heart failure: MR-pro-adrenomedullin. Clinical Chemistry and Laboratory Medicine. 2014;52(10):1433–5. DOI: 10.1515/cclm-2014-0222

41. Yasu T, Nishikimi T, Kobayashi N, Ikeda N, Ueba H, Nakamura T et al. Up-regulated synthesis of mature-type adrenomedullin in coronary circulation immediately after reperfusion in patients with anterior acute myocardial infarction. Regulatory Peptides. 2005;129(1–3):161–6. DOI: 10.1016/j.regpep.2005.02.008

42. Wang W, McKinnie SMK, Patel VB, Haddad G, Wang Z, Zhabyeyev P et al. Loss of Apelin Exacerbates Myocardial Infarction Adverse Remodeling and Ischemia‐reperfusion Injury: Therapeutic Potential of Synthetic Apelin Analogues. Journal of the American Heart Association. 2013;2(4):e000249. DOI: 10.1161/JAHA.113.000249

43. Japp AG, Cruden NL, Barnes G, Van Gemeren N, Mathews J, Ada mson J et al. Acute Cardiovascular Effects of Apelin in Humans: Potential Role in Patients With Chronic Heart Failure. Circulation. 2010;121(16):1818–27. DOI: 10.1161/CIRCULATIONAHA.109.911339

44. Lage R, Moscoso I, Fernández-Trasancos Á, Cebro M, Couselo M, Fandiño-Vaquero R et al. Differential behaviour of epicardial adipose tissue-secretomes with high and low orosomucoid levels from patients with cardiovascular disease in H9C2 cells. Molecular and Cellular Endocrinology. 2015;416:77–87. DOI: 10.1016/j.mce.2015.08.025

45. Cherian S, Lopaschuk GD, Carvalho E. Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease. American Journal of Physiology-Endocrinology and Metabolism. 2012;303(8):E937–49. DOI: 10.1152/ajpendo.00061.2012

46. Iacobellis G. Aging Effects on Epicardial Adipose Tissue. Frontiers in Aging. 2021;2:666260. DOI: 10.3389/fragi.2021.666260

47. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H et al. Human Epicardial Adipose Tissue Is a Source of Inflammatory Mediators. Circulation. 2003;108(20):2460–6. DOI: 10.1161/01.CIR.0000099542.57313.C5

48. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H et al. Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-κB Signaling Through a cAMP-Dependent Pathway. Circulation. 2000;102(11):1296–301. DOI: 10.1161/01.CIR.102.11.1296

49. Zhang T, Yang P, Li T, Gao J, Zhang Y. Leptin Expression in Human Epicardial Adipose Tissue Is Associated with Local Coronary Athe rosclerosis. Medical Science Monitor. 2019;25:9913–22. DOI: 10.12659/MSM.918390

50. Ghantous CM, Azrak Z, Hanache S, Abou-Kheir W, Zeidan A. Differential Role of Leptin and Adiponectin in Cardiovascular System. International Journal of Endocrinology. 2015;2015:534320. DOI: 10.1155/2015/534320

51. Packer M. Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. Journal of the American College of Cardiology. 2018;71(20):2360–72. DOI: 10.1016/j.jacc.2018.03.509

52. Poggi AL, Gaborit B, Schindler TH, Liberale L, Montecucco F, Carbone F. Epicardial fat and atrial fibrillation: the perils of atrial failure. EP Europace. 2022;24(8):1201–12. DOI: 10.1093/europace/euac015

53. Vyas V, Blythe H, Wood EG, Sandhar B, Sarker S-J, Balmforth D et al. Obesity and diabetes are major risk factors for epicardial adipose tissue inflammation. JCI Insight. 2021;6(16):e145495. DOI: 10.1172/jci.insight.145495

54. Zhou M, Wang H, Chen J, Zhao L. Epicardial adipose tissue and atrial fibrillation: Possible mechanisms, potential therapies, and future directions. Pacing and Clinical Electrophysiology. 2020;43(1):133–45. DOI: 10.1111/pace.13825

55. Терещенко С.Н. Галявич А.С., Ускач Т.М., Агеев Ф.Т., Арутюнов Г.П., Беграмбекова Ю.Л. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):311-74. DOI: 10.15829/1560-4071-2020-4083

56. Kitzman DW, Shah SJ. The HFpEF Obesity Phenotype: The Elephant in the Room. Journal of the American College of Cardiology. 2016;68(2):200–3. DOI: 10.1016/j.jacc.2016.05.019

57. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017;136(1):6–19. DOI: 10.1161/CIRCULATIONAHA.116.026807

58. Pérez-Belmonte LM, Moreno-Santos I, Gómez-Doblas JJ, García-Pinilla JM, Morcillo-Hidalgo L, Garrido-Sánchez L et al. Expression of epicardial adipose tissue thermogenic genes in patients with reduced and preserved ejection fraction heart failure. International Journal of Medical Sciences. 2017;14(9):891–5. DOI: 10.7150/ijms.19854

59. Choy M, Huang Y, Peng Y, Liang W, He X, Chen C et al. Association between epicardial adipose tissue and incident heart failure mediating by alteration of natriuretic peptide and myocardial strain. BMC Medicine. 2023;21(1):117. DOI: 10.1186/s12916-023-02836-4

60. Ateş K, Demir M. Importance of epicardial adipose tissue as a predictor of heart failure with preserved ejection fraction. Revista da Associação Médica Brasileira. 2022;68(9):1178–84. DOI: 10.1590/1806-9282.20220069

61. Chong B, Jayabaskaran J, Ruban J, Goh R, Chin YH, Kong G et al. Epicardial Adipose Tissue Assessed by Computed Tomography and Echocardiography Are Associated With Adverse Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation: Cardiovascular Imaging. 2023;16(5):e015159. DOI: 10.1161/CIRCIMAGING.122.015159

62. Pugliese NR, De Biase N, Mazzola M, Paneni F, Del Punta L, Gargani L et al. Prognostic significance of epicardial adipose tissue in heart failure with preserved and reduced ejection fraction. European Heart Journal. 2021;42(Suppl 1):ehab724.0820. DOI: 10.1093/eurheartj/ehab724.0820

63. Jin X, Hung C, Tay WT, Soon D, Sim D, Sung K et al. Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction. European Journal of Heart Failure. 2022;24(8):1346–56. DOI: 10.1002/ejhf.2513

64. Van Woerden G, Van Veldhuisen DJ, Westenbrink BD, De Boer RA, Rienstra M, Gorter TM. Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives. European Journal of Heart Failure. 2022;24(12):2238–50. DOI: 10.1002/ejhf.2741

65. Pugliese NR, Paneni F, Mazzola M, De Biase N, Del Punta L, Gargani L et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. European Journal of Heart Failure. 2021;23(11):1858–71. DOI: 10.1002/ejhf.2337

66. Venkateshvaran A, Faxen UL, Hage C, Michaëlsson E, Svedlund S, Saraste A et al. Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS‐HFpEF study. European Journal of Heart Failure. 2022;24(12):2251–60. DOI: 10.1002/ejhf.2709

67. Драпкина О.М., Самородская И.В., Старинская М.А., Ким О.Т., Неймарк А.Е. Ожирение: оценка и тактика ведения пациентов. Коллективная монография. - М.: НМИЦ ТПМ Минздрава России, ООО «Силицея-Полиграф»; 2021. – 176с. ISBN 978-5-9907556-0-4

68. Marcks N, Aimo A, Januzzi JL, Vergaro G, Clerico A, Latini R et al. Reappraisal of the obesity paradox in heart failure: a meta-analysis of individual data. Clinical Research in Cardiology. 2021;110(8):1280–91. DOI: 10.1007/s00392-021-01822-1

69. Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. The American Journal of Cardiology. 2003;91(7):891–4. DOI: 10.1016/S0002-9149(03)00031-6

70. Futter JE, Cleland JGF, Clark AL. Body mass indices and outcome in patients with chronic heart failure. European Journal of Heart Failure. 2011;13(2):207–13. DOI: 10.1093/eurjhf/hfq218

71. Brgdar A, Gharbin J, Elawad A, Khalafalla S, Bishaw A, Balogun AF et al. The Effects of Body Mass Index on In-Hospital Mortality and Outcomes in Patients With Heart Failure: A Nationwide Analysis. Cureus. 2022;14(2):e22691. DOI: 10.7759/cureus.22691

72. Adamson C, Jhund PS, Docherty KF, Bělohlávek J, Chiang C, Diez M et al. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure. 2021;23(10):1662–72. DOI: 10.1002/ejhf.2308

73. Заикина М.П., Капустина В.А., Савельев С.И. Парадокс ожирения при сердечно-сосудистых заболеваниях и сахарном диабете (аналитический обзор). Здравоохранение Российской Федерации. 2021;65(2):135-42. DOI: 10.47470/0044-197X-2021-65-2-135-142

74. Aldiss P, Davies G, Woods R, Budge H, Sacks HS, Symonds ME. ‘Browning’ the cardiac and peri-vascular adipose tissues to modu late cardiovascular risk. International Journal of Cardiology. 2017;228:265–74. DOI: 10.1016/j.ijcard.2016.11.074

75. Peczkowski KK, Mashali MA, Saad NS, Hare A, Campbell CM, Whitson BA et al. Quantification of Cardiac Adipose Tissue in Failing and Nonfailing Human Myocardium. Journal of the American Heart Association. 2022;11(13):e025405. DOI: 10.1161/JAHA.121.025405

76. Liu J, Yu Q, Li Z, Zhou Y, Liu Z, You L et al. Epicardial adipose tissue density is a better predictor of cardiometabolic risk in HFpEF patients: a prospective cohort study. Cardiovascular Diabetology. 2023;22(1):45. DOI: 10.1186/s12933-023-01778-8